Does timing of adjuvant chemotherapy for early breast cancer influence survival?

Shannon, C., Ashley, S. and Smith, I. E. (2003) Does timing of adjuvant chemotherapy for early breast cancer influence survival?. Journal of Clinical Oncology, 21 20: 3792-3797. doi:10.1200/JCO.2003.01.073

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads
UQ410615_OA.pdf application/pdf 90.21KB 0

Author Shannon, C.
Ashley, S.
Smith, I. E.
Title Does timing of adjuvant chemotherapy for early breast cancer influence survival?
Journal name Journal of Clinical Oncology   Check publisher's open access policy
ISSN 0732-183X
Publication date 2003-10-01
Sub-type Article (original research)
DOI 10.1200/JCO.2003.01.073
Open Access Status File (Publisher version)
Volume 21
Issue 20
Start page 3792
End page 3797
Total pages 6
Place of publication Alexandria, VA, United States
Publisher American Society of Clinical Oncology
Language eng
Formatted abstract
Purpose: Theoretically, patients with early breast cancer might benefit from starting adjuvant chemotherapy soon after surgery, and this would have important clinical implications. We have addressed this question from a large, single-center database in which the majority of patients received anthracyclines.

Patients and Methods: A total of 1,161 patients from a prospectively maintained database treated with adjuvant chemotherapy for early breast cancer at the Royal Marsden Hospital (London, United Kingdom), including 686 (59%) receiving anthracyclines, were retrospectively analyzed. The disease-free survival (DFS) and overall survival (OS) of the 368 patients starting chemotherapy within 21 days of surgery (group A) were compared with those of the 793 patients commencing chemotherapy ≥ 21 days after surgery (group B). Median follow-up time was 39 months (range, 12 to 147 months).

Results: No significant difference in 5-year DFS was found between the two groups overall (70% for group A v 72% for group B; P = .4) or in any subgroup. Likewise, there was no difference in 5-year OS (82% for group A v 84% for group B; P = .2) or when the interval to the start of chemotherapy was considered as a continuous variable (P = .4).

Conclusion: We have been unable to identify any significant survival benefit from starting adjuvant chemotherapy early after surgery, either overall or in any subset of patients.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Mater Health Services Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 51 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 61 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 01 Nov 2016, 21:06:37 EST by Cath Shannon on behalf of Mater Research Institute-UQ